BioPharma Drug Discovery

Clover Advances Global First In Class Respiratory Vaccine Strategy With Phase Two Launch

- Phase 2 Initiation Strengthens Global First-in-Class Potential for Clover's Protein-Based RSV + hMPV ± PIV3 Respiratory Combination Vaccine Candid...

 January 13, 2026 | News

China Approves ArkBio Aizhida For ADHD With Rapid Onset And All Day Symptom Control

Shanghai Ark Biopharmaceutical Co., Ltd. ("ArkBio") today announced that China's National Medical Products Administration (NMPA) has approved the...

 January 12, 2026 | News

Pierre Fabre Laboratories And Iktos Launch AI Driven Oncology Drug Discovery Alliance

Pierre Fabre Laboratories and Iktos, a global leader in Artificial Intelligence (AI) and Robotics on drug discovery, announced an integrated drug disc...

 January 12, 2026 | News

M&G Leads $50 Million Series C In bit.bio To Scale Human Cell Programming

M&G Investments (M&G) announces that it has led a US$50 million Series C funding round for bit.bio, the Cambridge-based biotech company pionee...

 January 12, 2026 | News

Johnson And Johnson Amivantamab Combo Delivers 73% Response Rate In First Line Metastatic Colorectal Cancer

Over 70 percent of patients in the first-line subgroup responded to amivantamab plus chemotherapy with most responses lasting beyond 16 months Notable res...

 January 12, 2026 | News

AirNexis Secures Global Rights To Phase 2 COPD Asset AN01 In $200 Million Series A Backed By Frazier And OrbiMed

AirNexis acquires exclusive rights to develop AN01 outside of China from Haisco Pharmaceutical Group Company founded by Frazier Life Sciences, which led...

 January 12, 2026 | News

Biocytogen And Acepodia Advance Dual Payload Bispecific ADC Strategy Through Option Based Licensing Pact

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315) and Acepodia (6976:TT), announced that the companies have entered int...

 January 12, 2026 | News

Zai Lab Secures China Approval For AUGTYRO In NTRK Fusion Positive Solid Tumours

-Zai Lab Limited  announced that China’s National Medical Products Administration (NMPA) has approved the supplemental New Drug Application (sND...

 January 09, 2026 | News

Oxeia Targets First Ever Treatment For Persistent Concussion Symptoms After Strong Phase 2a Results

Biotech showed 85% patient improvement in Phase 2a trial—zero approved treatments exist for persistent concussion symptoms Oxeia Biopharmaceuticals ...

 January 09, 2026 | News

Lilly To Acquire Ventyx Biosciences In $1.2 Billion Deal To Deepen Oral Inflammation Pipeline

Ventyx's clinical pipeline includes multiple small molecules with potential for oral therapies addressing chronic inflammation Acquisition builds on ...

 January 09, 2026 | News

Nuclera Secures First Commercial Sales In Asia With Landmark Installations In Taiwan

Installations at National Taiwan University and National Cheng Kung University expand Nuclera’s global footprint with first commercial sales in Asi...

 January 08, 2026 | News

Sichuan Kelun Biotech Secures NMPA IND Approval For SKB105 Antibody Drug Conjugate In Advanced Solid Tumours

 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech" or the "Company", 6990.HK) announced that its Investigational New Drug (IND) appli...

 January 07, 2026 | News

Shanghai Ark Biopharmaceutical Secures NMPA Approval For Azstarys ADHD Treatment In China

Shanghai Ark Biopharmaceutical Co., Ltd. ("ArkBio") announced that China's National Medical Products Administration (NMPA) has approved the New D...

 January 07, 2026 | News

C&R Research Deepens Indonesia Engagement Through Global Clinical Trial Capabilities

Accelerating Indonesia Collaboration through Global Clinical Capabilities  C&R Research, founded in 1997 as Korea's first full-service Contract R...

 January 06, 2026 | News


News

Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close